← Markets

Amylyx Pharmaceuticals, Inc.

AMLX · NASDAQ

Market closed$17.75$0.730000 (+4.29%)After hours $17.76 · +0.06%

Key statistics

Previous close$17.02
Open$16.70
Day high$18.07
Day low$16.57
52-week high$19.15
52-week low$7.48
Market cap1.48B
Volume1.19M
Average volume1.35M
P/E ratio-11.83
Forward P/E—
EPS-1.50
Dividend yield0.00%

Market context

Why it moved

AMLX shares moved higher, buoyed by positive analyst coverage and an upgraded price target noted in recent research on the stock, alongside anticipation of upcoming Phase 3 clinical trial data for avexitide expected in Q3 2026.

Yahoo FinancePluangInstagramMarketbeat

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026Amylyx Pharmaceuticals jumped amid a constructive backdrop for biotech, as UBS upgraded its sector outlook citing improving earnings revisions, a stabilizing regulatory environment, and a warming M&A environment as potential catalysts for the segment. Analyst price targets on AMLX remain well above current levels — Guggenheim has a $40 target and HC Wainwright a $34 target — while a fresh lobbying disclosure revealed $40,000 in Q2 spending focused on rare disease access and innovation, signaling continued policy engagement ahead of potential pipeline developments.

4.2891

July 15, 2026Amylyx Pharmaceuticals closed lower as investor attention turned to insider selling activity — the company's Chief Legal Officer Gina Mazzariello sold 30,000 shares totaling approximately $539,000 on July 9–10 under a pre-established Rule 10b5-1 plan. While planned insider sales are routine, the disclosure drew scrutiny amid an otherwise constructive backdrop for biotech, with UBS upgrading the healthcare sector and biotechnology names seen as beneficiaries of rising M&A activity and pipeline catalysts.

-2.3077

July 14, 2026Amylyx Pharmaceuticals gained over 4% during the session, outperforming both the broader healthcare sector (XLV edged slightly higher in after-hours) and the S&P 500 amid a mixed macro backdrop shaped by a cooler-than-expected June CPI print and Iran-related geopolitical uncertainty. The day's trading follows recent insider activity: Amylyx's Chief Legal Officer sold 30,000 shares under a pre-arranged Rule 10b5-1 plan on July 9–10, a routine scheduled sale that investors are monitoring alongside ongoing pipeline developments in the rare neurodegenerative disease space.

4.5376

July 14, 2026Amylyx Pharmaceuticals declined amid a broader market selloff driven by escalating U.S.-Iran tensions and a chip stock rout, with the healthcare sector also under modest pressure. Company-specific attention remains focused on the upcoming Phase 3 LUCIDITY readout for avexitide in post-bariatric hypoglycemia — a catalyst Guggenheim flagged as a Best Idea with a $40 price target — while insider selling by the CLO and a pending $6.5M class action settlement add to near-term investor caution.

-2.0259

July 11, 2026Amylyx Pharmaceuticals fell over 3% on elevated investor caution, underperforming the broader healthcare sector (XLV closed fractionally lower) even as biotech broadly has been touted as the market's hottest group. The stock has been in focus since its recent removal from several Russell equity indexes, a technical event that prompted index-tracking fund repositioning, though the company maintains an estimated fair value of ~$22.20 — suggesting the shares remain undervalued relative to fundamentals. Investor attention is anchored on avexitide's pivotal Phase III trial in post-bariatric hypoglycemia (PBH), with topline data expected Q3 2026 and a 2027 commercial launch targeted if results are positive; the company holds cash runway into 2028. An SEC Form 144 filing appeared on July 10, adding a minor sentiment overhang. In after-hours trading, shares partially recovered, edging back toward $18.00.

-3.3188

July 8, 2026Amylyx Pharmaceuticals closed down 1.60%, pressured by a broad risk-off session as renewed U.S.-Iran military strikes in the Persian Gulf rattled markets and pushed crude oil sharply higher. The healthcare sector held relatively firm amid the turbulence — XLV posted modest gains in after-hours — but Amylyx's own narrative remains centered on its late-stage pipeline: the pivotal Phase 3 LUCIDITY trial for avexitide in post-bariatric hypoglycemia and early Phase 1 LUMINA safety data for AMX0114 in ALS, with analysts citing a fair value near $22.20 versus current levels. The stock's removal from Russell indexes in late June created technical selling pressure, though its year-to-date gain of over 57% reflects strong underlying momentum.

-1.596

July 8, 2026Amylyx Pharmaceuticals closed modestly higher, buoyed by a favorable biotech backdrop after Jim Cramer called biotech 'the hottest group in the market' and predicted a wave of M&A dealmaking under the friendlier regulatory environment. The gain comes as analysts frame AMLX as potentially undervalued at ~$22.20 fair value, roughly 22% above the last close, even as the company navigates its late-June removal from multiple Russell equity indexes — a technical headwind that has pressured short-term trading flows without altering the core thesis around its pivotal Phase 3 LUCIDITY trial for avexitide and early encouraging Phase 1 LUMINA safety data for ALS candidate AMX0114.

1.113

July 7, 2026Amylyx Pharmaceuticals closed modestly lower amid a broader healthcare sector pullback, with the XLV health care ETF also under pressure on the day. Investor attention remains split between two key narratives: encouraging early Phase 1 LUMINA safety data for AMX0114 in ALS — showing no drug-related serious adverse events at the lowest dose and advancing to higher dose cohorts — and the company's removal from multiple Russell equity indexes in late June 2026, which has introduced technical selling pressure. Meanwhile, a law firm investigation into potential fiduciary duty breaches by certain officers and directors adds a governance overhang, even as analysts point to a $22.20 fair value and the pivotal LUCIDITY trial for avexitide in post-bariatric hypoglycemia as the key near-term catalyst.

-1.642

STAT · July 16, 2026Amylyx nears pivotal endocrine drug study readoutInvesting.com · June 25, 2026Guggenheim raises Amylyx stock price target on PBH drug outlookStock Titan · June 23, 2026Amylyx says ALS drug AMX0114 showed no serious safety issuesBusiness Wire · May 15, 2026Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical InvestigationStock Titan · May 15, 2026Amylyx AMX0035 improves diabetes control, steadies vision in rare diseaseSimply Wall Street · May 10, 2026Amylyx Readies Avexitide For PBH With Pivotal Trial And Valuation GapBusiness Wire · May 7, 2026Amylyx Pharmaceuticals Reports First Quarter 2026 Financial ResultsStock Titan · March 24, 202678-patient trial for post-surgery hypoglycemia heads to Q3 data
Benzinga · June 25, 2026Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $40
Benzinga · June 23, 2026Amylyx Pharma To Present Data From First-In-Human, Dose-Ranging Phase 1 LUMINA Trial Of AMX0114 At ENCALS Meeting 2026
Benzinga · May 15, 2026Amylyx Pharmaceuticals Publishes Data From Weeks 24, 48 Of Its Phase 2 HELIOS Study Of AMX0035 To Treat Wolfram Syndrome; Results Demonstrate Continued Improvements In Pancreatic Beta Cell Function Through Week 48
Mt Newswire · May 7, 2026Earnings Flash (AMLX) Amylyx Posts Q1 Loss $0.37 a Share, vs. FactSet Est of $0.35 Loss
Mt Newswire · April 29, 2026Mizuho Lifts Price Target on Amylyx Pharmaceuticals to $21 From $19, Maintains Outperform Rating
Mt Newswire · April 29, 2026Mizuho Adjusts Price Target on Amylyx Pharmaceuticals to $21 From $19, Maintains Outperform Rating
Benzinga · April 28, 2026Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $21
Benzinga · March 25, 2026HC Wainwright & Co. Reiterates Buy on Amylyx Pharmaceuticals, Maintains $34 Price Target

Peers

S&P 500SPX · $7,457.69-1.01%Mirum Pharmaceuticals, Inc.MIRM · $118.86+1.28%Rhythm Pharmaceuticals, Inc.RYTM · $106.60+0.48%PTC Therapeutics, Inc.PTCT · $78.59+0.09%Nuvation Bio Inc.NUVB · $5.80+2.84%Zevra Therapeutics, Inc.ZVRA · $12.77+0.08%EyePoint Pharmaceuticals, Inc.EYPT · $13.30+1.99%Sarepta Therapeutics, Inc.SRPT · $17.22-0.06%ANI Pharmaceuticals, Inc.ANIP · $79.20-3.32%Intellia Therapeutics, Inc.NTLA · $11.38-4.09%Zymeworks Inc.ZYME · $24.190.00%Denali Therapeutics Inc.DNLI · $23.29+2.46%